- $32.50m
- $43.15m
- $17.47m
- 45
- 61
- 47
- 49
Annual income statement for ImmuCell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13.7 | 15.3 | 19.2 | 18.6 | 17.5 |
Cost of Revenue | |||||
Gross Profit | 6.74 | 6.86 | 8.66 | 7.65 | 3.87 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 14.7 | 15.9 | 19 | 20.9 | 22.9 |
Operating Profit | -0.954 | -0.537 | 0.257 | -2.3 | -5.38 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.27 | -1.03 | -0.069 | -2.49 | -5.77 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.3 | -1.02 | -0.078 | -2.49 | -5.77 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.3 | -1.02 | -0.078 | -2.49 | -5.77 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.3 | -1.02 | -0.078 | -2.49 | -5.77 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.19 | -0.214 | -0.008 | -0.323 | -0.775 |